SAREUM HOLDINGS PLC

Earnings Release • Aug 22, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5815O

Sareum Holdings PLC

22 August 2017

(AIM: SAR)	22 August 2017

SAREUM HOLDINGS PLC

("Sareum" or "the Company")

Pre-Close Trading Statement

Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, provides the following trading update ahead of its full year results for the year ending 30 June 2017. 

The Company is pleased to report that subject to audit, it now expects that the profit for the year after tax and cash at bank, for its results for the year ended 30 June 2017, to be ahead of market expectations.

An update on progress with its cancer and autoimmune disease research and development programmes will be given in mid-late October 2017 when the Company expects to report its full year results.

For further information, please contact: 

Sareum Holdings plc
Tim Mitchell	01223 497 700
WH Ireland Limited (Nominated Adviser and Co-Broker)
Chris Fielding / James Sinclair-Ford	020 7220 1666
Hybridan LLP (Co-Broker)
Claire Noyce	020 3764 2341
Citigate Dewe Rogerson (Media enquiries)
Shabnam Bashir/ Mark Swallow/ David Dible	020 7282 9571

Notes for editors: 

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and licensing them to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum operates an outsourced research model, working with international collaborators and a world-wide network of research providers. Its most advanced programme (Chk1) commenced clinical trials in May 2016 and was licensed to NASDAQ-listed Sierra Oncology in September 2016.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3 and TYK2 kinase cancer and autoimmune disease research programmes, which are in the IND-enabling preclinical and lead optimisation stages respectively. SKIL® can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk

- Ends -

This information is provided by RNS

The company news service from the London Stock Exchange

END

TSTBSGDIRUDBGRB